The shares of Glaukos Corporation have decreased by more than -27.55% this year alone. The shares recently went down by -4.28% or -$1.11 and now trades at $24.85. The shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX), has jumped by 82.40% year to date as of 12/11/2017. The shares currently trade at $70.59 and have been able to report a change of -1.93% over the past one week.

The stock of Glaukos Corporation and Neurocrine Biosciences, Inc. were two of the most active stocks on Monday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

**Next 5Y EPS Growth: 40.00% versus 40.10% **

When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that GKOS will grow it’s earning at a 40.00% annual rate in the next 5 years. This is in contrast to NBIX which will have a positive growth at a 40.10% annual rate. This means that the higher growth rate of NBIX implies a greater potential for capital appreciation over the years.

**Profitability and Returns**

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. GKOS has an EBITDA margin of 1.42%, this implies that the underlying business of GKOS is more profitable. The ROI of GKOS is 3.60% while that of NBIX is -46.80%. These figures suggest that GKOS ventures generate a higher ROI than that of NBIX.

**Cash Flow **

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, GKOS’s free cash flow per share is a positive 0, while that of NBIX is negative -0.08.

**Liquidity and Financial Risk**

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for GKOS is 6.90 and that of NBIX is 14.40. This implies that it is easier for GKOS to cover its immediate obligations over the next 12 months than NBIX. The debt ratio of GKOS is 0.00 compared to 1.05 for NBIX. NBIX can be able to settle its long-term debts and thus is a lower financial risk than GKOS.

**Valuation**

GKOS currently trades at a forward P/E of 221.88, a P/B of 6.49, and a P/S of 5.60 while NBIX trades at a P/B of 17.96, and a P/S of 92.92. This means that looking at the earnings, book values and sales basis, GKOS is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

**Analyst Price Targets and Opinions**

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of GKOS is currently at a -43.37% to its one-year price target of 43.88. Looking at its rival pricing, NBIX is at a -20.76% relative to its price target of 89.08. This figure implies that over the next one year, NBIX is a better investment.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), GKOS is given a 1.50 while 1.60 placed for NBIX. This means that analysts are more bullish on the outlook for NBIX stocks.

**Insider Activity and Investor Sentiment**

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for GKOS is 5.95 while that of NBIX is just 9.70. This means that analysts are more bullish on the forecast for GKOS stock.

**Conclusion**

The stock of Neurocrine Biosciences, Inc. defeats that of Glaukos Corporation when the two are compared, with NBIX taking 3 out of the total factors that were been considered. NBIX happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, NBIX is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for NBIX is better on when it is viewed on short interest.